DonaldETsaiMD
Oncology • Philadelphia, PAHematologic Oncology
Associate Professor, Medicine, Perelman School of Medicine
Dr. Tsai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
15 Penn Tower
Philadelphia, PA 19104Phone+1 215-662-3914
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1996 - 2000- University of Pennsylvania Health SystemResidency, Internal Medicine, 1994 - 1996
Duke University School of MedicineClass of 1994
Certifications & Licensure
PA State Medical License 1995 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Bexarotene in Patients With Acute Myeloid Leukemia Start of enrollment: 2004 Jan 01
- Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia Start of enrollment: 2010 May 25
Publications & Presentations
PubMed
- 119 citationsThe Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative DisorderMarlise R. Luskin, Daniel S. Heil, Kay See Tan, Sarah Choi, Edward A. Stadtmauer
American Journal of Transplantation. 2015-10-01 - 52 citationsPirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel
The New England Journal of Medicine. 2023-07-06 - 232 citationsPirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Yoon Cheah, John M. Pagel
Lancet. 2021-03-06
Abstracts/Posters
- Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...Donald E. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...Donald E. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
